New insights into the clinical and nonclinical effects of psychedelic substances: an integrative review
Study at a glance
AI-extracted from the abstract| Characteristics | Review |
|---|---|
| Key findings | Psychedelic research has revived and shows potential for treating mental health disorders, with beneficial effects in clinical samples for major depression, anxiety, and substance use disorders, as well as effects on healthy subjects' wellbeing and cognition. |
Abstract
After decades of stagnancy, research on psychedelic substances (such as LSD, psilocybin or DMT) has experienced a renaissance over the last 10 years, with various major research programs being conducted across Europe and the United States. This research primarily investigates the potential of psychedelics in the treatment of mental health disorders, their short and long term effects on recreational users, and the neurological and cognitive processes responsible for their effects. The present review provides a concise summary of the most recent insights gained from this research. We briefly outline the history of psychedelic research, the objective and subjective effects caused by these substances, the prevalence and socio-psychological correlates of their use, as well as their potential for harm. Subsequently, we review empirical research on the beneficial effects of psychedelics in clinical samples, focusing on their efficacy in the treatment of major depression, anxiety, and substance use disorders, and discuss research on the proposed neural and cognitive mechanisms behind these effects. We then review research on their effects on healthy subjects, focusing on psychological wellbeing as well as changes in personality, nature relatedness, and creativity. Finally, we review empirical evidence regarding long-term effects of single experiences with psychedelics, and conclude with a brief summary and outlook.
Citations in the library
Cites 84
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
and 79 more in the library